Abstract 190P
Background
The combination of gemcitabine and nab-paclitaxel (GnP) has been established as the first-line chemotherapy in patients (pts) with metastatic pancreatic cancer (M-PC). However, the efficacy of the therapy in pts with borderline resectable PC (BR-PC) and locally advanced PC (LA-PC) is not clear. Although achieving R0 resection is one of the main target for these pts, the details of the response, such as the best time to evaluate the response is not clear. Therefore, we evaluated the details of response with GnP treatment.
Methods
We retrospectively reviewed the medical records of pts with BR-PC, LA-PC, and M-PC who received GnP as the first-line chemotherapy between January 2016 and April 2019 at six hospitals. We investigated time to response (TTR), duration of response (DoR), and depth of response (DpR). The response of the primary tumor and the metastases were evaluated separately in pts with M-PC. The response of the primary tumor was evaluated in all pts.
Results
A total of 47 pts were analyzed; the median age was 70 years, male was 66% and the number of pts with BR-PC/LA-PC/M-PC was 6%/26%/68%. The response rates of primary tumor and metastases were 40% and 31%, respectively. Among the pts with M-PC, seven had a partial response (PR) of the primary tumor without PR of metastases. The median TTR and time to best response of the primary tumor and metastases were 3.17 months (m) and 4.21 m (p = 0.191), and 4.11 m and 5.88 m (p = 0.724), respectively. The median DoR of the primary tumor and metastases were 5.36 m and 4.11 m, respectively (p = 0.277). The median DpR of the primary tumor and metastases were 28.3% and 15.3%, respectively (p = 0.733). The median progression-free survival and overall survival in M-PC pts with and without PR of the primary tumor were 8.48 m and 6.41 m (p = 0.267), and 14.72 m and 7.66 m (p = 0.186), respectively.
Conclusions
The response of the primary tumor tended to be higher and earlier than that of the metastases. A favorable efficacy was observed in pts with BR-PC and LA-PC as well as pts with M-PC. This study indicated that the best time to evaluate the response of the primary site to consider the conversion therapy was around 4 m. Pts with M-PC showing PR of the primary tumor tended to have a favorable prognosis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
259P - The BOT patients fail to benefit from surgical staging procedures in prognosis and fertility outcomes: A retrospective analysis
Presenter: Li Na
Session: Poster display session
Resources:
Abstract
260P - Malignant ovarian germ cell tumours (MOGCT): Treatment results of 149 pts
Presenter: Dzhennet Chekini
Session: Poster display session
Resources:
Abstract
261P - Ovarian germ cell tumours - challenges and outcomes from a tertiary care centre in South India
Presenter: Vishnu Sreedath
Session: Poster display session
Resources:
Abstract
262P - Gestational trophoblastic tumours: Experience of the medical oncology department Hassan II University Hospital-Morocco about 29 cases
Presenter: Karima Oualla
Session: Poster display session
Resources:
Abstract
263TiP - ATHENA (GOG-3020/ENGOT-ov45): A randomised, double-blind, placebo-controlled phase III study of the poly (ADP-ribose) polymerase (PARP) inhibitor rucaparib + the PD-1 inhibitor nivolumab following frontline platinum-based chemotherapy in ovarian cancer
Presenter: Keiichi Fujiwara
Session: Poster display session
Resources:
Abstract
264TiP - ENGOT-ov43/KEYLYNK-001: A phase III trial of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of BRCA¬-nonmutated advanced epithelial ovarian cancer
Presenter: Keiichi Fujiwara
Session: Poster display session
Resources:
Abstract
265TiP - KEYNOTE-826: A phase III randomized study of chemotherapy with or without pembrolizumab for first-line treatment of persistent, recurrent, or metastatic cervical cancer
Presenter: Keiichi Fujiwara
Session: Poster display session
Resources:
Abstract
271P - Comparison between CHOP like regimens and DAEPOCH with or without Rituximab in adult high grade B cell lymphoma NOS; A retrospective study from a tertiary cancer hospital in South India
Presenter: LALATENDU MOHARANA
Session: Poster display session
Resources:
Abstract
272P - Melatonin increases the chemosensitivity of diffuse large Bell lymphoma cells to Epirubicin by inhibiting P-glycoprotein expression via the NF-κB pathway
Presenter: Xiuhua Sun
Session: Poster display session
Resources:
Abstract
273P - MALT1- A20 and NF-κB expression pattern in patients with non-Hodgkin lymphomas
Presenter: Alshimaa Alhanafy
Session: Poster display session
Resources:
Abstract